New York, NY -- (SBWire) -- 10/01/2018 --Various types of drug-eluting stents (DES) are available in the market and has dramatically revolutionized the coronary artery disease (CAD) revascularization. This results in the decline in rates of major adverse cardiac events (MACE), and target lesion revascularization (TLR) and become a trend of revascularization in patients with CAD. Therefore, adoption of first-generation DES such as Cyper (Johnson & Johnson Company), and Taxus (Boston Scientific) is reduced due to certain limitations such as late stent thrombosis. This lead to the introduction of next-generation drug-eluting stents offering lower restenotic rates as compared to bare metal stents (BMS) and permits more complicated lesions to be treated. Next-generation drug-eluting stent is advantageous as it offers improved deliverability by using materials like cobalt chromium, cobalt nickel, and cobalt alloy, this results in significant reduction in strut width, and enhance stent flexibility. In next-generation drug eluting stent, several drugs are coated in stents to address multiple restenosis pathways by altering drug release kinetics that mimics restenosis cascade. In addition, next-generation drug-eluting stent utilizes bioabsorbable polymers to reduce complications of late stent thrombosis, and bioresorbable drug-eluting scaffold plays a vital role in transforming coronary artery disease treatment.
Next-generation drug-eluting stent market is primarily driven by elevating a number of geriatric population on the global level as they are at high risk of developing arterial disorders. In addition, increasing prevalence and incidence of atherosclerosis pertaining to unhealthy lifestyle and obesity are also driving the growth of the next-generation drug eluting stents market. For instance, according to the research conducted, more than 15.8 million individual is suffering from coronary artery disease, and approximately 8 million of them have has heart attack. However, factors such as reduction in the drug-eluting stents pricing, and availability of alternative therapy procedure are the major obstacle to the market growth of next-generation drug eluting stent. Increasing preference for drugs over the surgical procedure of stent implants and increased risk of developing late-stage thrombosis are limiting the growth of next-generation drug-eluting stent market.
Request for Report Sample : https://www.persistencemarketresearch.com/samples/20842
The global next generation drug eluting stent market can be segmented on the basis of polymer type, material type, end-user, and region.
On the basis of polymer type, global next generation drug eluting stent market can be segmented as:
Durable Polymer
Bioabsorbable Polymer
On the basis of material type, global next generation drug eluting stent market can be segmented as:
Cobalt chromium
Stainless Steel
Others
On the basis of end user, global next generation drug eluting stent market can be segmented as:
Hospitals
Clinics
Ambulatory surgical Centers
Request for Report TOC : https://www.persistencemarketresearch.com/toc/20842
Next-Generation Drug-Eluting Stent Market Value Projected to Expand by 2025
Persistence Market Research has announced the addition of the “Next-Generation Drug-Eluting Stent Market" report to their offering.